全部集團訊息
-
United BioPharma Received Approval from China NMPA for a Phase 1 Trial with UB-221 in Healthy Volunteers
United BioPharma Received Approval from China NMPA for a Phase 1 Trial with UB-221 in Healthy VolunteersUnited BioPharma Received Approval from China NMPA for a Phase 1 Trial with UB-221 in Healthy Volunteersmore -
PharmaBoardroom’s Women to Watch 2020
PharmaBoardroom’s Women to Watch 2020PharmaBoardroom’s Women to Watch 2020more -
聯生藥愛滋病治療抗體新藥UB-421榮獲第十六屆國家新創獎年度續獎「新創精進獎」
聯生藥愛滋病治療抗體新藥UB-421榮獲第十六屆國家新創獎年度續獎「新創精進獎」聯生藥愛滋病治療抗體新藥UB-421榮獲第十六屆國家新創獎年度續獎「新創精進獎」more -
聯生藥與美國NIH/NIAID簽署合作執行UB-421 應用於 多重抗藥性HIV感染病患之臨床試驗協議
聯生藥與美國NIH/NIAID簽署合作執行UB-421 應用於 多重抗藥性HIV感染病患之臨床試驗協議聯生藥與美國NIH/NIAID簽署合作執行UB-421 應用於 多重抗藥性HIV感染病患之臨床試驗協議more -
United BioPharma Signs clinical trial agreement with NIH/NIAID for sponsorship of a multi-drug resistant HIV trial with UB-421
United BioPharma Signs clinical trial agreement with NIH/NIAID for sponsorship of a multi-drug resistant HIV trial with UB-421United BioPharma Signs clinical trial agreement with NIH/NIAID for sponsorship of a multi-drug resistant HIV trial with UB-421more -
聯生藥單株抗體新藥UB-221獲美國FDA核准 在慢性自發性蕁麻疹患者進行臨床一期試驗
聯生藥單株抗體新藥UB-221獲美國FDA核准 在慢性自發性蕁麻疹患者進行臨床一期試驗聯生藥單株抗體新藥UB-221獲美國FDA核准 在慢性自發性蕁麻疹患者進行臨床一期試驗more -
United BioPharma Receives US FDA Approval for UB-221 Phase 1 IND for Chronic Spontaneous Urticaria
United BioPharma Receives US FDA Approval for UB-221 Phase 1 IND for Chronic Spontaneous UrticariaUnited BioPharma Receives US FDA Approval for UB-221 Phase 1 IND for Chronic Spontaneous Urticariamore
